Bukwang Pharmaceutical IND says CP-012 trial costs to continue until next year, growth to continue led by Latuda
Predicted impact: Low
Trial cost timing and Latuda growth outlook; no quantified financial impact given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.